- Home
- TSAT vs LXEO Comparison
TSAT vs LXEO Comparison
Compare TSAT & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TSAT | LXEO |
|---|---|---|
| Founded | 1969 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.8M | 663.5M |
| IPO Year | 1996 | 2023 |
Fundamental Metrics
Financial Performance| Metric | TSAT | LXEO |
|---|---|---|
| Price | $29.16 | $9.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $18.90 |
| AVG Volume (30 Days) | 113.0K | ★ 1.5M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $324,440,552.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.31 | $1.45 |
| 52 Week High | $36.85 | $10.99 |
Technical Indicators
Market Signals| Indicator | TSAT | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 50.25 | 52.72 |
| Support Level | $28.65 | $10.02 |
| Resistance Level | $31.00 | $10.99 |
| Average True Range (ATR) | 2.16 | 0.59 |
| MACD | -0.14 | -0.03 |
| Stochastic Oscillator | 21.63 | 45.64 |
Price Performance
Historical ComparisonAbout TSAT Telesat Corporation
Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.